Abiopharma

🔍 Pagliari Aldo John (Executive)

Company: Snap-on Inc (SNA)

Report Date: 2026-08-13

Detailed Transactions and Holdings:

• Acquired 8,000 shares of Common Stock at $168.7 per share (Direct)
  Date: 2026-08-13 | Code: M | equity_swap_involved: 0 | shares_owned_after: 126,175.12 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,447 shares of Common Stock at $403.136 per share (Direct)
  Date: 2026-08-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 124,728.12 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 2,564 shares of Common Stock at $403.9026 per share (Direct)
  Date: 2026-08-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 122,164.12 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 441 shares of Common Stock at $404.9451 per share (Direct)
  Date: 2026-08-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 121,723.12 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 831 shares of Common Stock at $405.9376 per share (Direct)
  Date: 2026-08-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 120,892.12 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 208 shares of Common Stock at $406.9759 per share (Direct)
  Date: 2026-08-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 120,684.12 | transaction_form_type: 4 | Footnotes: F1, F7
• Sold 40 shares of Common Stock at $409.69 per share (Direct)
  Date: 2026-08-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 120,644.12 | transaction_form_type: 4 | Footnotes: F1
• Sold 8,000 shares of Stock Option (Right to Buy) at $168.7 per share (Derivative)
  Date: 2026-08-13 | Code: M | Expires: 2027-02-09 | equity_swap_involved: 0 | shares_owned_after: 10,000.00 | transaction_form_type: 4 | Footnotes: F1, F9, F8
• Holds 26,052 shares of Stock Option (Right to Buy) at $161.18 per share (Derivative)
  Date: 2026-08-13 | Code: H | Expires: 2028-02-15 | shares_owned_after: 26,052.00 | Footnotes: F8
• Holds 23,500 shares of Stock Option (Right to Buy) at $155.92 per share (Derivative)
  Date: 2026-08-13 | Code: H | Expires: 2029-02-14 | shares_owned_after: 23,500.00 | Footnotes: F8
• Holds 23,500 shares of Stock Option (Right to Buy) at $155.34 per share (Derivative)
  Date: 2026-08-13 | Code: H | Expires: 2030-02-13 | shares_owned_after: 23,500.00 | Footnotes: F8
• Holds 14,986 shares of Stock Option (Right to Buy) at $189.89 per share (Derivative)
  Date: 2026-08-13 | Code: H | Expires: 2031-02-11 | shares_owned_after: 14,986.00 | Footnotes: F8
• Holds 11,252 shares of Stock Option (Right to Buy) at $211.67 per share (Derivative)
  Date: 2026-08-13 | Code: H | Expires: 2032-02-10 | shares_owned_after: 11,252.00 | Footnotes: F8
• Holds 7,850 shares of Stock Option (Right to Buy) at $249.26 per share (Derivative)
  Date: 2026-08-13 | Code: H | Expires: 2033-02-09 | shares_owned_after: 7,850.00 | Footnotes: F8
• Holds 7,106 shares of Stock Option (Right to Buy) at $269.0 per share (Derivative)
  Date: 2026-08-13 | Code: H | Expires: 2034-02-15 | Exercise: 2025-02-15 | shares_owned_after: 7,106.00 | Footnotes: F10
• Holds 5,342 shares of Stock Option (Right to Buy) at $339.73 per share (Derivative)
  Date: 2026-08-13 | Code: H | Expires: 2035-02-13 | Exercise: 2026-02-13 | shares_owned_after: 5,342.00 | Footnotes: F10
• Holds 5,187 shares of Stock Option (Right to Buy) at $378.55 per share (Derivative)
  Date: 2026-08-13 | Code: H | Expires: 2036-02-12 | Exercise: 2027-02-12 | shares_owned_after: 5,187.00 | Footnotes: F10
• Holds 1,533 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-13 | Code: H | Expires: 2027-02-15 | Exercise: 2027-02-15 | shares_owned_after: 1,533.00 | Footnotes: F11, F12, F12
• Holds 1,249 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-13 | Code: H | Expires: 2028-02-13 | Exercise: 2028-02-13 | shares_owned_after: 1,249.00 | Footnotes: F11, F12, F12
• Holds 1,249 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-13 | Code: H | Expires: 2029-02-12 | Exercise: 2029-02-12 | shares_owned_after: 1,249.00 | Footnotes: F11, F12, F12
• Holds 3,065 shares of Performance Units (Derivative)
  Date: 2026-08-13 | Code: H | shares_owned_after: 3,065.00 | Footnotes: F11, F13, F13
• Holds 2,498 shares of Performance Units (Derivative)
  Date: 2026-08-13 | Code: H | shares_owned_after: 2,498.00 | Footnotes: F11, F14, F14
• Holds 2,497 shares of Performance Units (Derivative)
  Date: 2026-08-13 | Code: H | shares_owned_after: 2,497.00 | Footnotes: F11, F15, F15

Footnotes:

• F1: The option was exercised, and a portion of the underlying shares were sold to cover the exercise price and estimated tax liability, pursuant to a Rule 10b5-1 Plan, which was adopted on November 3, 2025.
• F2: Includes 17.4326 shares acquired under a dividend reinvestment plan.
• F3: This transaction was executed in multiple trades at prices ranging from $402.43 to $403.41. The price reported above reflects the weighted average sale price. the reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effectuated.
• F4: This transaction was executed in multiple trades at prices ranging from $403.45 to $404.42. The price reported above reflects the weighted average sale price. the reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effectuated.
• F5: This transaction was executed in multiple trades at prices ranging from $404.45 to $405.41 The price reported above reflects the weighted average sale price. the reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effectuated.
• F6: This transaction was executed in multiple trades at prices ranging from $405.50 to $406.47. The price reported above reflects the weighted average sale price. the reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effectuated.
• F7: This transaction was executed in multiple trades at prices ranging from $406.56 to $407.29. The price reported above reflects the weighted average sale price. the reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effectuated.
• F8: Option fully vested.
• F9: Exercise of Rule 16b-3 stock option pursuant to a Rule 10b5-1 Plan, which was adopted on November 3, 2025.
• F10: Original stock option grant vests in three annual installments beginning on the date listed in the "Date Exercisable" column.
• F11: 1 for 1.
• F12: The restricted stock units vest three years from the grant date on the date listed above, assuming continued employment.
• F13: If the Company achieves certain goals over the 2024-2026 period, the performance units will vest and stock will be awarded. The target number of units that may be earned is reported above; the maximum amount is 200% of the number reported, subject to plan limits.
• F14: If the Company achieves certain goals over the 2025-2027 period, the performance units will vest and stock will be awarded. The target number of units that may be earned is reported above; the maximum amount is 200% of the number reported, subject to plan limits.
• F15: If the Company achieves certain goals over the 2026-2028 period, the performance units will vest and stock will be awarded. The target number of units that may be earned is reported above; the maximum amount is 200% of the number reported, subject to plan limits.